Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case–control study

Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case–control study

Abstract MYCN-amplified RB1 wild-type (MYCN amp RB1 +/+) retinoblastoma is a rare and aggressive subtype, often resistant to standard therapies. Identifying unique MRI features is crucial for diagnosing this subtype, as biopsy is not recommended. This study aimed to differentiate MYCN amp RB1 +/+ fr...

Full description

Bibliographic Details
Main Authors: Christiaan M. de Bloeme, Robin W. Jansen, Liesbeth Cardoen, Sophia Göricke, Sabien van Elst, Jaime Lyn Jessen, Aparna Ramasubramanian, Alison H. Skalet, Audra K. Miller, Philippe Maeder, Ogul E. Uner, G. Baker Hubbard, Hans Grossniklaus, H. Culver Boldt, Kim E. Nichols, Rachel C. Brennan, Saugata Sen, Mériam Koob, Selma Sirin, Hervé J. Brisse, Paolo Galluzzi, Charlotte J. Dommering, Matthijs Cysouw, Ronald Boellaard, Josephine C. Dorsman, Annette C. Moll, Marcus C. de Jong, Pim de Graaf, European Retinoblastoma Imaging Collaboration
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
Retinoblastoma
MRI; radiomics 
MYCN-amplification
Online Access:https://doi.org/10.1038/s41598-024-76933-6

Internet

https://doi.org/10.1038/s41598-024-76933-6

Similar Items